福泰制药 (Viatris) has agreed to acquire Crinetics Pharmaceuticals Inc. for approximately $10 billion, marking the largest transaction in the company's history. This acquisition aims to expand Viatris's presence in the endocrinology sector. The deal, valued at $85 per share in cash, represents a 102% premium over Crinetics's closing price and is expected to close in the third quarter, pending regulatory approvals. AI
RANK_REASON Significant acquisition by a major pharmaceutical company. [lever_c_demoted from significant: ic=1 ai=0.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
